The relationship between psoriasis and psoriasis arthritis and osteoporosis

August 1, the Rheumatology Yearbook published online the research article "Systematic Evaluation of the Relationship between Psoriasis, Psoriasis Arthritis and Osteoporosis" by PI Zheng Houfeng of the School of Life Sciences of West Lake University, which clarifies the relationship between psoriasis (commonly known as psoriasis) and psoriasis arthritis and osteoporosis.
Zheng Houfeng was a dermatologist, during his M.D. research topic is around psoriasis genetic research, in Canada McGill University postdoctoral research, Zheng Houfeng turned to bone metabolism-related genetic research, so both diseases are more understood. According to reports, psoriasis is a common autoimmune skin disease, the incidence rate in the European population is 2.5%, the incidence rate of the Asian population is 0.1%-0.5%, of which the most serious complication is psoriasis arthritis. Although a large number of previous studies have focused on the relationship between psoriasis and osteoporosis, the results of many studies have been inconsistent due to potential confluency factors, or the inability to collect sufficient data in its entirety, leading to the current debate about whether psoriasis can lead to osteoporosis.
how to determine whether there is a attribution relationship between psoriasis and osteoporosis has become an important clinical problem. On the basis of big data, Zheng Houfeng's team analyzed the relationship between the two more comprehensively, and came to reliable conclusions, which provided new evidence for clinical guidelines.
their study found that psoriasis patients had significantly lower bone mass than the control group, but the association was not determined by genetic factors, i.e. there was no attribution. They speculate that secondary causes osteoporosis (e.g. by taking medication or lack of exercise).
In order to prove this, they included psoriasis arthritis patients taking drugs and physical exercise factors, through intermediary analysis methods, found that psoriasis arthritis to reduce bone density risk effect is indeed 63% through the use of drugs (methotrexate, cyclosporine) indirectly mediated, and physical exercise intermediary role of 8%. Based on the non-attribution hypothesis, non-arthritis psoriasis patients are not a potential risk factor for bone reduction or osteoporosis because there is no secondary effect.
, they found that men with psoriasis arthritis had a higher pronounced difference in bone mass characteristics than women in the control group. They speculated that the possible reason was that most of the women included in the study were post-menopapa, and that the lack of estrogen may have a greater effect on bone density than psoriasis arthritis.
it should be emphasized that the study included 432,513 sample data from the UK's large sample database for cross-sectional observational studies, at which there was sufficient statistical certainty to study the relationship between exposure and outcome.
For clinical applications, Zheng's team recommends that patients with psoriasis arthritis, especially those treated with methotrexate or cyclosporine, be regularly screened for bone volume reduction and risk of osteoporosis, and that appropriate health management be provided to reduce the risk of fractures. (Source: Wen Caifei, China Science Journal)
related paper information: